A more recent study of 189 AML patients (without APL), including a non-AML patient control group, showed that at diagnosis, the average level of expression of S100A8 and S100A9 mRNA was in fact lower in AML patients than those in the control group [33]. This evidence concerns the gene S100A9 and acute promyelocytic leukemia.